Novo Nordisk (NVO) PT Lowered to $46 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Evan Seigerman lowered the price target on Novo Nordisk (NYSE: NVO) to $46.00 (from $50.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
